Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.64 |
| ▸ | EGFR | P00533 | 7/20 | 0.64 |
| ▸ | RET | P07949 | 1/20 | 0.64 |
| ▸ | KIF5B | P33176 | 1/20 | 0.64 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | INSR | P06213 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 12/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2100447 | 0.86 | KDR (0.80) | KDREGFRRETKIF5BEPHB4 | |
| SCHEMBL907212 | 0.84 | KDR (0.71) | KDREGFRRETKIF5BEPHB4 | |
| SCHEMBL22630824 | 0.84 | KDR (0.69) | KDREGFRRETKIF5BEPHB4 | |
| SCHEMBL31067694 | 0.82 | KDR (0.83) | KDREGFRRETKIF5BFLT4 | |
| SCHEMBL906971 | 0.80 | KDR (0.64) | KDREGFRRETKIF5BEPHB4 | |
| SCHEMBL22630825 | 0.80 | KDR (0.77) | KDREGFRRETKIF5BEPHB4 | |
| SCHEMBL907182 | 0.80 | KDR (0.77) | KDREGFRRETKIF5BEPHB4 | |
| SCHEMBL22590721 | 0.80 | EGFR (0.80) | KDREGFRRETKIF5BEPHB4 | |
| SCHEMBL13497856 | 0.79 | EGFR (0.85) | KDREGFREPHB4ERBB2AURKA | |
| SCHEMBL5864546 | 0.79 | KDR (0.82) | KDREGFRRETKIF5BEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| EP-2280003-A2 | Process for preparing receptor-type kinase modulators | Symphony Evolution, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2277867-A2 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | Symphony Evolution, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | KDR 17/4885EGFR 1/4885RET 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.